Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial

医学 吉西他滨 卡培他滨 内科学 临床终点 胃肠病学 人口 肿瘤科 化疗 随机对照试验 外科 癌症 结直肠癌 环境卫生
作者
Hyehyun Jeong,Kyu‐pyo Kim,Jae Ho Jeong,Dae Wook Hwang,Jae Hoon Lee,Ki‐Hun Kim,Deok‐Bog Moon,Myung Ah Lee,Se Jun Park,Hong Jae Chon,Jin‐hong Park,Ji Sung Lee,Baek‐Yeol Ryoo,Changhoon Yoo
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:77 (5): 1540-1549 被引量:72
标识
DOI:10.1097/hep.0000000000000046
摘要

BACKGROUND AND AIMS: The effectiveness of gemcitabine-based adjuvant chemotherapy is unclear in cholangiocarcinoma. We investigated the role of adjuvant gemcitabine plus cisplatin (GemCis) in a homogeneous group of high-risk patients with resected, lymph node-positive extrahepatic cholangiocarcinoma. APPROACH AND RESULTS: Adenocarcinoma of perihilar or distal bile duct with regional lymph node metastasis who underwent curative-intent surgery (R0/R1) was eligible. Patients were randomized to receive GemCis (gemcitabine 1000 mg/m2, cisplatin 25 mg/m2 on days 1 and 8) or capecitabine (1250 mg/m2 twice daily on days 1-14) every 3 weeks for 8 cycles. Primary endpoint was disease-free survival. Secondary endpoints were overall survival and safety. All p values are 1 sided and were considered significant if <0.1. Between July 2017 and November 2020, 101 patients (50 in the GemCis and 51 in the capecitabine group) were included in the intention-to-treat population. Perihilar and distal bile ducts were the primary sites in 45 (44.6%) and 56 (55.4%) patients, respectively, and 32 (31.7%) had R1 resections. Median (1-sided 90% CI) follow-up duration was 33.4 (30.5-35.8) months. In the GemCis and capecitabine group, 2-year disease-free survival rates were 38.5% (29.5%-47.4%) and 25.1% (17.4%-33.5%) [HR=0.96 (CI, 0.71-1.30), p=0.430], and median overall survival was 35.7 months (29.5-not estimated) and 35.7 months (30.9-not estimated) [HR=1.08 (CI, 0.71-1.64), 1-sided p=0.404], respectively. Grade 3-4 adverse events occurred in 42 (84.0%) and 8 patients (16.0%) in the GemCis and capecitabine groups, respectively. No treatment-related deaths were reported. CONCLUSIONS: In resected lymph node-positive extrahepatic cholangiocarcinoma, adjuvant GemCis did not improve survival outcomes compared with capecitabine.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
童diedie完成签到,获得积分10
1秒前
Czz发布了新的文献求助10
2秒前
荼蘼发布了新的文献求助30
2秒前
乐乐的应助被忐忑的远望采纳,获得10
2秒前
3秒前
小一完成签到,获得积分20
3秒前
3秒前
Rocky完成签到,获得积分10
3秒前
4秒前
4秒前
缓慢的孱的应助被虚心的向秋采纳,获得10
5秒前
7秒前
李爱国的应助被FGGFGGU采纳,获得10
7秒前
李健的应助被LIU采纳,获得10
7秒前
SciGPT的应助被飘飘采纳,获得10
7秒前
Hello的应助被细腻驳采纳,获得10
7秒前
Aaa__JiAn完成签到,获得积分10
8秒前
8秒前
怪默完成签到,获得积分10
9秒前
专注数据线完成签到,获得积分20
10秒前
qqww2233发布了新的文献求助30
10秒前
11秒前
开放满天发布了新的文献求助10
11秒前
miaomiao完成签到,获得积分10
11秒前
11秒前
12秒前
Abracadabra的应助被chen采纳,获得10
12秒前
13秒前
13秒前
14秒前
CodeCraft的应助被静哥哥采纳,获得10
14秒前
14秒前
15秒前
15秒前
pumpkin完成签到,获得积分10
16秒前
16秒前
SRJ完成签到,获得积分10
16秒前
村民发布了新的文献求助30
17秒前
花呗发布了新的文献求助20
17秒前
木子发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241